DGX - Quest Diagnostics Incorporated
After hours:
| Previous close | 135.67 |
| Open | 135.60 |
| Bid | 132.80 x 800 |
| Ask | 136.54 x 800 |
| Day's range | 134.24 - 135.57 |
| 52-week range | 120.40 - 158.34 |
| Volume | |
| Avg. volume | 1,061,887 |
| Market cap | 15.071B |
| Beta (5Y monthly) | 0.94 |
| PE ratio (TTM) | 19.61 |
| EPS (TTM) | 6.86 |
| Earnings date | 19 Jul 2023 - 24 Jul 2023 |
| Forward dividend & yield | 2.84 (2.11%) |
| Ex-dividend date | 10 Jul 2023 |
| 1y target est | 146.93 |
ZacksImplied Volatility Surging for Quest Diagnostics (DGX) Stock Options
Investors need to pay close attention to Quest Diagnostics (DGX) stock based on the movements in the options market lately.
ZacksQuest Diagnostics' (DGX) Contract Wins Aid Amid Volume Woes
Quest Diagnostics (DGX) succeeds on contract wins in its reference and professional lab services offerings.
ZacksOption Care (OPCH) Surges 6.3%: Is This an Indication of Further Gains?
Option Care (OPCH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
ZacksReasons to Retain Quest Diagnostics (DGX) Stock for Now
Investors are optimistic about Quest Diagnostics (DGX) on the strength of the base business performance and its strategies to accelerate growth.
Motley FoolWant Growing Passive Income? Consider Buying This Stock
As one of the largest diagnostic companies in the United States, Quest Diagnostics (NYSE: DGX) is vitally important to the healthcare sector. Prior to the pandemic, Quest Diagnostics was already an impressive company, serving 1-in-3 American adults and half of the hospitals in the U.S. Thanks to its commitment to innovation, the company was able to quickly respond to the pandemic by launching five different types of COVID-19 tests. This provided a temporary boost to its growth prospects: Full-year revenue surged 14.3% in 2021 to $10.8 billion, and adjusted diluted earnings per share (EPS) soared 27.4% for the year to $14.24.
- Investing.com
5 big analyst cuts: AMD booted off buy list after Q2 outlook | Pro Recap
Here is your Pro Recap of the biggest analyst cuts you may have missed on InvestingPro since yesterday: downgrades at AMD, Comerica, Quest Diagnostics, Corox, and E2open. Advanced Micro Devices (NASDAQ:AMD) was skidding lower in the premarket Wednesday after sluggish Q2 guidance, which prompted Bank of America to downgrade it to Hold from Buy and to trim its price target to $95 from the prior $98. BofA sees a "range of headwinds" for the company, including "aggressive pricing/promotion pressure from main rival {Intel," as well as concerns on second-half data center growth, lackluster positioning in AI accelerators, and limited room for further expansion in its price-to-earnings multiple until revenue "re-accelerates back to historical levels."
- Zacks
Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down
Quest Diagnostics (DGX) base business registers growth in the first quarter of 2023.
- Reuters
Quest Diagnostics beats profit estimates as routine testing demand returns
Demand for routine diagnostic tests has picked up as an increasing number of people return to the healthcare system for routine care after delaying care during the pandemic. Healthcare giant Abbott Laboratories and hospital operator HCA Healthcare Inc last week sounded optimistic about demand for medical device procedures, routine diagnostic testing and consumer-based health products, as cases of COVID-19 infection decline.
ZacksQuest Diagnostics (DGX) Beats Q1 Earnings and Revenue Estimates
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 3.55% and 5.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ZacksHenry Schein (HSIC) to Report Q1 Earnings: What's in Store?
Henry Schein's (HSIC) medical business is expected to have gained from improved U.S. patient traffic to physician offices, ultimate care sites and ambulatory surgical centers.
- Zacks
Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?
Quest Diagnostics' (DGX) first-quarter 2023 results are likely to reflect an impressive performance in its non-COVID-19 base business amid inflationary pressure and labor challenges.
ZacksAlign Technology (ALGN) to Post Q1 Earnings: What's in Store?
Align Technology's (ALGN) first-quarter 2023 results are likely to witness impressive performance across its operating segments amid macroeconomic pressure.
- Zacks
Quest Diagnostics (DGX) Advances Access to Transplant Services
Quest Diagnostics' (DGX) upgrade to advanced diagnostics and support services is likely to feature personalized patient access to service centers and mobile phlebotomists.
ZacksHow to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
ZacksWhy Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
ZacksQuest Diagnostics (DGX) Upgraded to Buy: What Does It Mean for the Stock?
Quest Diagnostics (DGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Zacks
Quest Diagnostics (DGX) Introduces New Post-COVID-19 Panels
Quest Diagnostics' (DGX) latest panels provide consumers a deeper look into their health, helping to prepare them for meaningful discussions with their healthcare providers
- Zacks
Quest Diagnostics (DGX) Advances Transplant Testing Service
These services by Quest Diagnostics (DGX) are available to recipients and living donors across the United States (excluding Alaska and Hawaii), broadening access for both donor and patient.
ZacksQuest Diagnostics (DGX) Acquires Northern Light Laboratory
Quest Diagnostics (DGX) now offers professional laboratory management services for nine of Northern Light Health's hospital laboratories.
ZacksWant Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
- Zacks
Quest Diagnostics (DGX) Updates Its Strategic Focus, LT Growth
Quest Diagnostics (DGX) is building strong platforms to focus on high-growth areas like molecular genomics and oncology.
Motley FoolIs This Healthcare Stock a Buy for Dividend Growth Investors?
This maker of diagnostics tests just announced that it will be sending more cash to its shareholders.
ZacksEnsign Group's (ENSG) Buyout Consolidates Colorado Presence
The Ensign Group (ENSG) buys two skilled nursing facilities in Colorado, aiming to expand its portfolio of nursing homes in the state.
ZacksAre Investors Undervaluing Quest Diagnostics (DGX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Zacks
Reasons to Add Quest Diagnostics (DGX) Stock to Your Portfolio
Investors continue to be optimistic about Quest Diagnostics (DGX) on its accelerated growth strategy and improvements in base volumes.
